Introduction
In 2019, the North America market for biosimilar was USD xx Billion and it is expected to reach USD yy Billion by 2025. 2015 was the first time when any Biosimilar got approval from US FDA. Since then 26 Biosimilars are approved in the US whereas 15 of those are marketed till date. US market is still not so easy for entry of Biosimilars as pharma / biopharma companies are still preferring more Biologics. The stakeholders need to put up a joint push for adaptability of Biosimilars because the innovators still have strong incentives to save their market share. Other hurdles include threat of patent litigation, development cost, less awareness to physicians and patients about effectiveness of biosimilars, strong incentives for biologics, etc. Still there is some ease in restrictions such as recent US FDA’s new guidelines on Biosimilars interchangeability is one of the welcoming steps. Whereas recent amendment in reimbursements & incentives is also expected to be very useful, such as Medicare Part B as well as 340B programs can be very useful in providing good incentives to physicians for approving / recommending the biosimilars to patients.
Benefits to the US Market
There are plenty of benefits for adoption of Biosimilars such as cost saving on account of patients, more utilization of supply chain, more potential incentives to physicians, etc. Below we are discussing it in little details:
Other benefits include Support Programs for Patients, Availability of Pre-clinical & Clinical Data, as well as Real World Evidence generation.
Below is a small list of Biosimilars which are approved by FDA in recent past.
As per the research segments such as Anti-TNF, Monoclonal Antibodies, and immunostimulants alone will contribute to more than 70% of total expected savings in very near future.
Major Manufacturers
The profiles for major manufacturers include Amgen, Boehringer Ingelheim, Celltrion, Teva, Coherus BioSciences, Fresenius Kabi, Mylan, Biocon, Pfizer, Samsung Bioepis, Merck, Sandoz, & Xbrane Biopharma
Segmentation
Biosimilars Market can be segmented into the following:
By Products:
By Application
By Region
To get a copy of Table of Contents (ToC), Report Blue Print or Sample Copy please Click HERE
To get a copy of List of Deliverables please share your requirements HERE
We offer customized reports as per our customers requirements. This covers a 360 degree deliverable scope study such as:
This section covers very brief quick reports as a scale down version of original Market Research report. You may be any of the following:
Please don’t worry and write to us HERE
For any other discussion such as related to various reports, future business requirements, feasibility discussion, etc. Or for talk to our sales team executive please feel free to reach out to us HERE
bd@essentialmarketinsights.com
+91 882 525 4416